Literature DB >> 29472629

Indication to pelvic lymph nodes dissection for prostate cancer: the role of multiparametric magnetic resonance imaging when the risk of lymph nodes invasion according to Briganti updated nomogram is <5.

Francesco Porpiglia1, Matteo Manfredi2, Fabrizio Mele2, Riccardo Bertolo2, Enrico Bollito3, Dario Gned4, Agostino De Pascale4, Filippo Russo5, Roberto Passera6, Cristian Fiori2, Stefano De Luca2.   

Abstract

BACKGROUND: The Briganti updated nomogram (BN) is the most popular predictive model aiming to predict the presence of lymph node invasion (LNI) in patients with prostate cancer (PCa), but it lacks information obtained by preoperative imaging. The primary aim of the study was to evaluate the role of multiparametric prostate magnetic resonance imaging (mp-MRI) in the indication to perform pelvic lymph nodes dissection (PLND) or not in patients with risk of LNI according to BN below 5%.
METHODS: Since March 2012 and September 2016, 310 patients who underwent a preoperative mp-MRI for staging purpose and subsequent robot-assisted extended PLND (RAEPLND) were retrospectively evaluated. Mp-MRIs were prospectively analyzed by two experienced radiologists. The imaging parameters analyzed were the presence of extracapsular extension (ECE), seminal vesicles invasion (SVI) and predominant Gleason pattern 4 (pG4). All patients underwent RAEPLND by two experienced surgeons with a standardized technique. A dedicated uropathologist performed all pathological analysis. Univariate analysis and multivariate logistic regression analysis were used in order to identify the predictors of LNI in patients with PCa.
RESULTS: In the overall population, 57 (18.4%) patients had histologically proven pN1 disease. 48/250 patients (19.2%) with a risk of LNI ≥5% as calculated by the BN were staged pN1 at final histopathological analysis. 9/60 patients (15.0%) with a risk of LNI <5% as calculated by BN, who underwent RAEPLND anyway according to the findings at mp-MRI, were staged pN1 at final histopathological analysis. At multivariate logistic regression analysis, all the three mp-MRI parameters were significant independent predictors of LNI after RAEPLND.
CONCLUSIONS: The role of mp-MRI seemed to be crucial in patients with a risk of LNI <5% as calculated by the BN. The presence of ECE, SVI, or pG4 at mp-MRI was found to be an independent predictor of LNI by itself.

Entities:  

Mesh:

Year:  2018        PMID: 29472629     DOI: 10.1038/s41391-017-0026-5

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  4 in total

1.  Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only.

Authors:  Cristian Fiori; Enrico Checcucci; Ilaria Stura; Daniele Amparore; Sabrina De Cillis; Alberto Piana; Stefano Granato; Gabriele Volpi; Michele Sica; Federico Piramide; Paolo Verri; Matteo Manfredi; Stefano De Luca; Riccardo Autorino; Giuseppe Migliaretti; Francesco Porpiglia
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-06-24       Impact factor: 5.554

Review 2.  Patients with Positive Lymph Nodes after Radical Prostatectomy and Pelvic Lymphadenectomy-Do We Know the Proper Way of Management?

Authors:  Bartosz Małkiewicz; Miłosz Knura; Małgorzata Łątkowska; Maximilian Kobylański; Krystian Nagi; Dawid Janczak; Joanna Chorbińska; Wojciech Krajewski; Jakub Karwacki; Tomasz Szydełko
Journal:  Cancers (Basel)       Date:  2022-05-08       Impact factor: 6.575

3.  The impact of lymphovascular invasion in patients with prostate cancer following radical prostatectomy and its association with their clinicopathological features: An updated PRISMA-compliant systematic review and meta-analysis.

Authors:  Wei Jiang; Lijin Zhang; Bin Wu; Zhenlei Zha; Hu Zhao; Yuan Jun; Yuefang Jiang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

Review 4.  A narrative review of pelvic lymph node dissection in prostate cancer.

Authors:  Douglas C Cheung; Neil Fleshner; Shomik Sengupta; Dixon Woon
Journal:  Transl Androl Urol       Date:  2020-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.